Quantcast
Channel: Australia Headlines on One News Page [United States]
Viewing all 53225 articles
Browse latest View live

Two-Test ban for SA's Rabada after Smith incident

0
0
Two-Test ban for SA's Rabada after Smith incident South Africa's Kagiso Rabada is banned for the rest of the Test series against Australia after being found guilty of deliberately making contact with Steve Smith. Reported by BBC Sport 2 hours ago.

Sport24.co.za | TIMELINE: Rabada's route to suspension

0
0
Proteas fast bowler Kagiso Rabada was suspended by the International Cricket Council following the second Test match against Australia Reported by News24 2 hours ago.

Mitchell Marsh picks up groin injury and fine for swearing

0
0
It was an unhappy day all round for the 26-year-old as Australia were beaten by six wickets in the second Test at Port Elizabeth. Reported by Brisbane Times 1 hour ago.

Sport24.co.za | CSA seeking legal advice on Rabada appeal

0
0
Cricket South Africa and Kagiso Rabada might still appeal the decision to suspend him for two Test matches and effectively end his series against Australia. Reported by News24 2 hours ago.

Man wears high-heels to work because they make him feel empowered

0
0
Ashley Maxwell-Lam, a project manager for a major bank in Sydney, Australia, has been wearing six-inch stilettos to work for about a year and claims they make him feel empowered. Reported by Myjoyonline 1 hour ago.

Q&A recap: Is Australia big enough to contain 'Big Tony' and 'Big Bob'?

0
0
The Big Question arising from Monday’s population-heavy Big Australia edition of Q&A: is Australia Big Enough to contain Big Tony and Big Bob? Reported by Brisbane Times 32 minutes ago.

Cricket-Contrite Rabada wants to learn from latest ban

0
0
PORT ELIZABETH, South Africa, March 12 (Reuters) - A contrite Kagiso Rabada admits he has let his team down after his two-test suspension significantly weakened South Africa’s chances of winning their home test series against Australia. Reported by Reuters India 47 minutes ago.

SOLIDIUM LAUNCHES ACCELERATED BOOKBUILT OFFERING OF SAMPO A-SHARES

0
0
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW

Solidium Oy today, 12 March 2018, announces an offering of 10.6 million A-shares in Sampo plc representing approximately 1.9 per cent of the outstanding shares in Sampo (the "Equity Offering"). The books for the Equity Offering will open with immediate effect. The shares offered in the Equity Offering will be placed in an accelerated bookbuilt offering to Finnish and international institutional investors. The current ownership interest of Solidium in Sampo is approximately 67 million shares, representing approximately 12 per cent of the outstanding shares. Danske Bank, Nordea and UBS Investment Bank are acting as Joint Bookrunners for the Equity Offering. 

Solidium will use the proceeds from the Equity Offering mainly to finance new equity investments and to repay the exchangeable bonds maturing in September 2018.

"The continued excellent development of Sampo Group has led to a situation where the company's share of Solidium's total investment assets has reached a high level, almost 35 per cent. By offering approximately one-sixth of our stake we will balance our portfolio, but will continue as a significant shareholder of Sampo", says Solidium's CEO *Antti Mäkinen*.

Solidium expects to announce the outcome of the Equity Offering during 13 March 2018. Solidium has agreed not to dispose of any further Sampo shares for a period of 90 days subject to certain customary exceptions. 

Solidium is a limited company wholly owned by the State of Finland. Its mission is to strengthen and stabilise Finnish ownership in nationally important companies and increase the value of its holdings in the long term. The basis and core objective of Solidium's strategy is proper, value-enhancing asset management of its current holdings. Through its stakes, Solidium is a minority owner in eleven significant listed companies: Elisa, Kemira, Konecranes, Metso, Outokumpu, Outotec, Sampo, SSAB, Stora Enso, Tieto and Valmet. The value of Solidium's total investment assets is approximately 9.0 billion euros.

*Further information:* CEO Antti Mäkinen, Solidium Oy, +358 50 561 1501

*Important notice*

THIS ANNOUNCEMENT HAS BEEN MADE FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO BUY, SELL, ISSUE OR SUBSCRIBE FOR, OR THE SOLICITATION OF AN OFFER TO BUY, SELL, ISSUE OR SUBSCRIBE FOR ANY SECURITIES, NOR SHALL THERE BE ANY SALE OF SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

MEMBERS OF THE GENERAL PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE EQUITY OFFERING. THIS ANNOUNCEMENT AND ANY OFFER OF SECURITIES TO WHICH IT RELATES ARE ONLY ADDRESSED TO AND DIRECTED AT PERSONS WHO ARE (1) QUALIFIED INVESTORS WITHIN THE MEANING OF DIRECTIVE 2003/71/EC AND ANY RELEVANT IMPLEMENTING MEASURES (THE "PROSPECTUS DIRECTIVE") AND (2) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS WHO FALL WITHIN ARTICLE 19(1) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER") OR ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC) OF THE ORDER OR ARE PERSONS TO WHOM AN OFFER OF THE SECURITIES REFERRED TO HEREIN MAY OTHERWISE LAWFULLY BE MADE (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THE INFORMATION REGARDING THE EQUITY OFFERING SET OUT IN THIS ANNOUNCEMENT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

THIS ANNOUNCEMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA). THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE INTO THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION. NO PUBLIC OFFERING OF SECURITIES IS BEING MADE IN THE UNITED STATES.

ANY INVESTMENT DECISION TO BUY SECURITIES IN THE EQUITY OFFERING MUST BE MADE SOLELY ON THE BASIS OF PUBLICLY AVAILABLE INFORMATION WHICH HAS NOT BEEN INDEPENDENTLY VERIFIED BY THE JOINT BOOKRUNNERS OR THE SELLER. NEITHER THIS ANNOUNCEMENT NOR ANY COPY OF IT MAY BE TAKEN, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES, AUSTRALIAN, CANADIAN, JAPANESE OR OTHER APPLICABLE SECURITIES LAWS.

THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFERING OR SALE OF THE SECURITIES REFERRED TO HEREIN IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. NO ACTION HAS BEEN TAKEN BY THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE AFFILIATES OR ANY OTHER PERSON THAT WOULD PERMIT AN OFFER OF THE SECURITIES REFERRED TO HEREIN OR POSSESSION OR DISTRIBUTION OF THIS ANNOUNCEMENT OR ANY OTHER OFFERING OR PUBLICITY MATERIAL RELATING TO THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED BY THE JOINT BOOKRUNNERS TO INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS.

THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR THE SELLER AND NO ONE ELSE IN CONNECTION WITH THE EQUITY OFFERING. THE JOINT BOOKRUNNERS WILL NOT REGARD ANY OTHER PERSON (WHETHER OR NOT A RECIPIENT OF THIS ANNOUNCEMENT) AS THEIR CLIENT IN RELATION TO THE EQUITY OFFERING AND THE JOINT BOOKRUNNERS WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN THE SELLER FOR PROVIDING THE PROTECTIONS AFFORDED TO THEIR CLIENTS NOR FOR GIVING ADVICE IN RELATION TO THE OFFERING OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO IN THIS ANNOUNCEMENT. THE JOINT BOOKRUNNERS MAY PARTICIPATE IN THE OFFERING ON A PROPRIETARY BASIS. Reported by GlobeNewswire 1 hour ago.

Solidium Oy: SOLIDIUM LAUNCHES ACCELERATED BOOKBUILT OFFERING OF SAMPO A-SHARES

0
0
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE ... Reported by FinanzNachrichten.de 1 hour ago.

Delivery Hero AG: Issuance of new shares in connection with existing stock option program and sale of shares for option holders by way of accelerated bookbuilding

0
0
DGAP-News: Delivery Hero AG / Key word(s): Capital Increase

12.03.2018 / 17:41
The issuer is solely responsible for the content of this announcement.
--------------------

*Delivery Hero: Issuance of new shares in connection with existing stock option program and sale of shares for option holders by way of accelerated bookbuilding.*

*Berlin, March 12, 2018* - The management board of Delivery Hero AG ("Delivery Hero"), with the consent of the supervisory board, today resolved to issue new shares under exclusion of shareholders' subscription rights with regard to the existing stock option program for current and former employees, directors and supporters of Delivery Hero and its subsidiaries. Up to 1.366.311 new ordinary registered shares ("New Shares"), representing up to approx. 0.75% of Delivery Hero's share capital, will be issued to beneficiaries of the stock option program who have exercised their stock options. Delivery Hero's share capital will be increased through a partial exercise of its existing authorized capital that had been granted for this specific purpose by an amount of up to EUR 1,366,311 from EUR 182,498,900 to up to EUR 183,865,211. The New Shares, like all other outstanding shares of Delivery Hero, will carry full dividend rights as of January 1, 2017 and be admitted to trading and included in the existing quotation for Delivery Hero's shares on the Frankfurt Stock Exchange.

Approximately 1.26 million of these New Shares will be offered to institutional investors for purchase through an accelerated bookbuilt offering upon direction and for the benefit of certain beneficiaries, inter alia, so that they can finance the exercise prices and income taxes. Members of Delivery Hero's management board and supervisory board did not exercise any stock options. UniCredit Bank AG acts as Sole Bookrunner on the share placement.

Disclaimer

This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of Delivery Hero AG or of any of its subsidiaries in the United States of America, Germany or any other jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities referred to herein may not be offered or sold in the United States of America in the absence of registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the 'Securities Act'). The securities of Delivery Hero AG have not been, and will not be, registered under the Securities Act.

In the United Kingdom, this announcement is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the 'Order') or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as 'Relevant Persons'). This document must not be acted on, or relied upon, by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In member states of the European Economic Area which have implemented Directive 2003/71/EC and any amendments thereto, in particular, Directive 2010/73/EU, this announcement and any offer, if made subsequently, is directed exclusively at persons who are 'qualified investors' within the meaning of the Prospectus Directive.

No action has been taken that would permit an offering or acquisition of the securities or a distribution of this announcement in any jurisdiction where such action would be unlawful. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

This release may contain forward looking statements, estimates, opinions and projections with respect to anticipated future performance of Delivery Hero AG ("forward-looking statements"). These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes,""estimates,""anticipates,""expects,""intends,""may,""will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of Delivery Hero AG and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release. We undertake no obligation, and do not expect to publicly update, or publicly revise, any of the information, forward-looking statements or the conclusions contained herein or to reflect new events or circumstances or to correct any inaccuracies which may become apparent subsequent to the date hereof, whether as a result of new information, future events or otherwise. We accept no liability whatsoever in respect of the achievement of such forward-looking statements and assumptions.

In connection with the transaction described above (the 'Placement'), UniCredit Bank AG is acting exclusively for Delivery Hero AG. It will not regard any other person as its clients in relation to the transaction and will neither be responsible nor provide protection to anyone other than Delivery Hero AG, nor will it provide advice to anyone other than Delivery Hero AG in relation to the Placement, the contents of this announcement or any other matter referred to herein.

In connection with the Placement, UniCredit Bank AG and any of its affiliates, acting as investors for their own accounts, may subscribe for or purchase securities of Delivery Hero AG and may otherwise deal for their own accounts. Accordingly, references to the securities being issued or sold should be read as including any issue, offer or sale to UniCredit Bank AG and any of its affiliates acting as investors for their own accounts. In addition UniCredit Bank AG or its affiliates may enter into financing arrangements and swaps with investors in connection with which UniCredit Bank AG (or its affiliates) may from time to time acquire, hold or dispose of Delivery Hero AG's shares. UniCredit Bank AG does not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

Neither UniCredit Bank AG nor any of its directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or, with limited exception, other information relating to Delivery Hero AG, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

Solely for the purpose of the product governance requirements contained within; (a) EU Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares wich will be offered in the Placement (the 'Offer Shares') have been subject to a product approval process, which has determined that the Offer Shares are; (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, the price of the Offer Shares may decline and investors could lose all or part of their investment; the Offer Shares offer no guaranteed income and no capital protection; and an investment in the Offer Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering.

Contact:
Bodo v. Braunmühl
Head of Corporate Communications
bodo.braunmuehl@deliveryhero.com --------------------

12.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: Delivery Hero AG
Oranienburger Straße 70
10117 Berlin
Germany
Phone: +49 (0)30 5444 59 000
Fax: +49 (0)30 5444 59 024
E-mail: info@deliveryhero.com
Internet: www.deliveryhero.com
ISIN: DE000A2E4K43
WKN: A2E4K4
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
 
End of News DGAP News Service Reported by EQS Group 1 hour ago.

Kiadis Pharma N. V.: Kiadis Pharma launches a private placement of approximately 2.6 million new shares

0
0
*                                               *   
* **Kiadis Pharma launches a private placement of approximately 2.6 million new shares*

*Amsterdam, The Netherlands, March 12, 2018 - Kiadis Pharma N.V. **("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS)*, a clinical stage biopharmaceutical company developing a T-cell immunotherapy product designed to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT), today announces the launch of a private placement of approximately 2.6 million new shares to institutional investors, representing approximately 14.8% of the Company's current issued share capital (the "Placing"). Existing shareholders of the Company will not have pre-emptive rights in relation to the new shares to be issued. The new shares will rank pari passu in all respects with the currently outstanding shares of the Company. With the capital increase, the Company intends to make full use of the remaining authority that the shareholders meeting has granted to the Company's Management and Supervisory Boards to issue new shares.

Kiadis Pharma intends to use the net proceeds of the Placing to:

· continue the Phase 3 international, randomized, controlled, multicentre clinical trial for ATIR101 in the United States, Canada and Europe;
· generate additional manufacturing capacity at vendors and to refurbish, equip and staff its leased manufacturing facility;
· further prepare the Company for commercialization by investing into a commercial organization, market access preparation and reimbursement discussions;
· support further production process optimization of ATIR;
· expand the organization to accommodate the increased number of activities;
· start a further clinical trial to assess the benefit of ATIR101 in conjunction with another T-cell depleted hematopoietic stem cell transplantation (HSCT) protocol or with a cyclophosphamide-based haplo transplantation protocol;
· apply funds for debt repayment, capital expenditures, general and administrative expenses, general corporate purposes in line with Kiadis Pharma's strategy and other working capital needs; and
· finance potential opportunities to broaden and diversify the research and development portfolio (e.g. through in-licensing or acquiring programs and companies with synergistic or complementary technologies, products and/or product candidates).

The new shares will be placed with institutional investors through an accelerated bookbuilding process and the subscription price and the number of shares to be issued in the Placing will be determined through this process. The bookbuilding period for the Placing will commence today with immediate effect and will close at short notice.

In relation to the Placing, the Company has, subject to customary exemptions, agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share issuances. In addition, and also subject to customary exemptions, the two largest shareholders of the Company (funds represented by and/or affiliated with Life Sciences Partners and Draper Esprit, together representing 43.8% of the share capital of the Company) as well as all members of the Company's Management Board and Supervisory Board have agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share disposals.

The Company will announce the number of new shares placed and the subscription price in the Placing in a subsequent press release expected to be published before the beginning of trading on Euronext Amsterdam and Euronext Brussels on Tuesday March 13, 2018.

A registration document, approved by the Netherlands Authority for the Financial Markets (AFM) on March 12, 2018, is available free of charge on the Company's website (www.kiadis.com). A summary and securities note, which together with the registration document will form the listing prospectus on the basis of which the new shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels, will be submitted to the AFM with a view to receiving its approval on or about March 13, 2018, following which it will be made available free of charge on the Company's website (www.kiadis.com).  

Jefferies International Limited is acting as Sole Bookrunner, Canaccord Genuity Limited as Lead Manager, Chardan as Co-Lead Manager and LifeSci Capital LLC as Co-Manager in connection with the Placing. Saola Healthcare Partners is acting as financial advisor to the Company.

*About Kiadis Pharma*
Kiadis Pharma's allodepleted T-cell immunotherapy product, given after a haploidentical hematopoietic stem cell transplantation (HSCT), is designed to reduce Graft versus Host Disease (GVHD). Single dose Phase 2 data with lead product ATIR101(TM) in patients with blood cancer shows a strong and clinically very relevant improvement over literature for the Baltimore protocol, with reduced risk of GVHD. Based on the positive results from the Phase 2 trial, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101(TM) across the EU as an adjunctive treatment in HSCT for malignant disease. Kiadis Pharma received Day 120 questions in September 2017 and is on track for potential (conditional) approval in Q4 2018 and launch in H2 2019. Kiadis Pharma is conducting a Phase 3 trial with ATIR101(TM) across Europe and North America (head to head against the Baltimore protocol). The first patient was enrolled in December 2017.

In September 2017 the US Food and Drug Administration (FDA) granted ATIR101(TM) the Regenerative Medicine Advanced Therapy (RMAT) designation. ATIR101(TM) has been granted Orphan Drug Designations both in the US and Europe.

The Company's shares are listed on Euronext Amsterdam and Brussels under the ticker KDS.

Website: www.kiadis.com

Company presentation: http://www.kiadis.com/company-presentation/

*For more information, please contact:*

*Kiadis Pharma:*
Karl Hård
Head of IR & Communications
Tel. +31 611 096 298
k.hard@kiadis.com  

 

*Important Notices*

This announcement not for distribution, directly or indirectly, in whole or in part, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada, Japan, South Africa or any other jurisdiction where to do so might constitute a violation or breach of any applicable law or regulation. This announcement is not a prospectus for the purposes of the Prospectus Directive (as defined below). This announcement is for information purposes only and is not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy securities of Company in the United States, Australia, Canada, Japan, South Africa or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction, and the distribution of this communication in jurisdictions may be similarly restricted. This announcement should not be regarded as an opinion or recommendation concerning the purchase or sale of securities of the Company. Persons into whose possession this communication comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdictions.

The securities mentioned herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), and may not be offered or sold in the United States absent registration under the US Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the US Securities Act. There will be no public offering of securities in the United States.

In the United Kingdom this announcement is only being distributed to, and is only directed at, and any investment or investment activity to which this announcement relates is available only to, and will be engaged in only with, qualified investors as defined in the Prospectus Directive who are (i) investment professionals falling with Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) other persons to whom it may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). Persons who are not relevant persons should not take any action on the basis of this announcement and should not act or rely on it.

The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area. With respect to any Member State of the European Economic Area and which has implemented the Prospectus Directive (each a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (i) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (ii) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purpose of this paragraph, the expression "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable the investor to decide to exercise, purchase or subscribe for the securities, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State. Notwithstanding the foregoing, in the Netherlands the shares are not and may not be offered other than to persons or entities who or which are qualified investors (gekwalificeerde beleggers) as defined in Section 1:1 of the Dutch Financial Supervision Act (Wet op het financieel toezicht) and in Belgium the shares may not be offered other than to persons or entities who or which are qualified investors as defined in Article 10§1 of the Belgian law dated 16 June 2006 (Wet op de openbare aanbieding van beleggingsinstrumenten en de toelating van beleggingsinstrumenten tot de verhandeling op een gereglementeerde markt).

Any investment decision in connection with the Placing must be made on the basis of all publicly available information relating to the Company and the new shares to be placed. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This announcement does not purport to identify or suggest the risks (direct or indirect) which may be associated with an investment in the Company or the new shares.

The new shares shall be admitted to listing and trading on Euronext Amsterdam on the basis of a listing prospectus, consisting of a registration document (the "Registration Document") and a summary and securities note (the "Summary and Securities Note"). The Registration Document, approved by the AFM on March 12, 2018, is available free of charge on the Company's website (www.kiadis.com). The Summary and Securities Note will contain a description of risks and uncertainties relating to holding shares in the Company. These risks and uncertainties include, among others: (i) the ownership of the Shares is highly concentrated and your interests may conflict with the interests of the Company's significant shareholders; (ii) U.S. and other non-Dutch holders of the Shares may be unable to exercise pre-emptive rights; (iii) the Company does not intend to pay dividends for the foreseeable future; (iv) the Company believes that it was a passive foreign investment company (PFIC) during its 2014, 2015, 2016 and 2017 taxable years and that it may be so as well during its 2018 taxable year, generally resulting in adverse tax consequences to U.S. investors; and (v) any sale, purchase or exchange of Shares may become subject to a common financial transaction tax. The Summary and Securities Note shall be made generally available via the Company's website (www.kiadis.com) if and when approved by the AFM.

In connection with any offering of the new shares, each of Jefferies International Limited ("Jefferies"), Canaccord Genuity Limited ("Canaccord"), Chardan Capital Markets, LLC ("Chardan") and LifeSci Capital LLC ("LifeSci Capital" and, together with Jefferies, Canaccord and Chardan, the "Banks") and any of their respective affiliates acting as an investor for their own account may take up as a proprietary position any new shares and in that capacity may retain, purchase or sell for their own account such new shares. In addition, any of them or their respective affiliates may enter into financing arrangements and swaps with investors in connection with which that any of them (or their affiliates) may from time to time acquire, hold or dispose of new shares. None of the Banks or any of their respective affiliates intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so.

None of the Banks or any of their respective affiliates, directors, officers, employees, advisers and agents accepts any responsibility or liability whatsoever for/or makes any representation or warranty, express or implied, as to the truth, fullness, accuracy or completeness of the information in this document (or whether any information has been omitted from the document) or any other information relating to the Company or its associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

None of the Company, the Banks or any of their respective affiliates directors, officers, employees, agents, affiliates or advisers is under any obligation to update, complete, revise or keep current the information contained in this document to which it relates or to provide the recipient of with access to any additional information that may arise in connection with it.

Jefferies and Canaccord are each authorised and regulated in the United Kingdom by the Financial Conduct Authority. Each of the Banks is acting exclusively for the Company and no one else in connection with this announcement or any future transaction in connection with it.

None of the Banks or any of their respective affiliates will regard any other person (whether or not a recipient of this document) as a client or will be responsible to anyone other than the Company for providing the protections afforded to its clients or for the giving of advice in relation to the contents of this announcement or any transaction, matter or arrangement referred to in this announcement.

The Company's managing director and CEO Arthur Lahr is responsible for arranging for the release of this announcement on behalf of Kiadis Pharma N.V.

This announcement contains statements about the Company that are or may be forward-looking statements. All statements other than statements of historical facts included in this announcement may be forward-looking statements. Without limitation, any statements preceded or followed by or that include the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or words or terms of similar substance or the negative thereof are forward-looking statements. These forward-looking statements are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of any such person to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions. No undue reliance should be placed on any forward-looking statement, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to the Company or any persons acting on their behalf are expressly qualified in their entirety by this statement. Reported by GlobeNewswire 1 hour ago.

Commonwealth Games: Wales Women's sevens squad includes Olympian Jaz Joyce

0
0
Commonwealth Games: Wales Women's sevens squad includes Olympian Jaz Joyce BBC Local News: Mid Wales -- Team Wales announces its women's sevens squad for next month's Commonwealth Games in Australia and include Olympian Jaz Joyce. Reported by BBC Local News 1 hour ago.

South Africa' Kagiso Rabada suspended for rest of Australia series

0
0
Mitchell Marsh was also fined 20 percent of his match fee. Reported by DNA 54 minutes ago.

Kiadis Pharma N. V.: CORRECTION (Includes Disclaimers) Kiadis Pharma launches a private placement of approximately 2.6 million new shares

0
0
*Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan, south africa or Any other jurisdiction in which such release, publication or distribution would be unlawful*
* **                                              *   

*Kiadis Pharma launches a private placement of approximately 2.6 million new shares*

*Amsterdam, The Netherlands, March 12, 2018 - Kiadis Pharma N.V. **("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS)*, a clinical stage biopharmaceutical company developing a T-cell immunotherapy product designed to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT), today announces the launch of a private placement of approximately 2.6 million new shares to institutional investors, representing approximately 14.8% of the Company's current issued share capital (the "Placing"). Existing shareholders of the Company will not have pre-emptive rights in relation to the new shares to be issued. The new shares will rank pari passu in all respects with the currently outstanding shares of the Company. With the capital increase, the Company intends to make full use of the remaining authority that the shareholders meeting has granted to the Company's Management and Supervisory Boards to issue new shares.

Kiadis Pharma intends to use the net proceeds of the Placing to:

· continue the Phase 3 international, randomized, controlled, multicentre clinical trial for ATIR101 in the United States, Canada and Europe;
· generate additional manufacturing capacity at vendors and to refurbish, equip and staff its leased manufacturing facility;
· further prepare the Company for commercialization by investing into a commercial organization, market access preparation and reimbursement discussions;
· support further production process optimization of ATIR;
· expand the organization to accommodate the increased number of activities;
· start a further clinical trial to assess the benefit of ATIR101 in conjunction with another T-cell depleted hematopoietic stem cell transplantation (HSCT) protocol or with a cyclophosphamide-based haplo transplantation protocol;
· apply funds for debt repayment, capital expenditures, general and administrative expenses, general corporate purposes in line with Kiadis Pharma's strategy and other working capital needs; and
· finance potential opportunities to broaden and diversify the research and development portfolio (e.g. through in-licensing or acquiring programs and companies with synergistic or complementary technologies, products and/or product candidates).

The new shares will be placed with institutional investors through an accelerated bookbuilding process and the subscription price and the number of shares to be issued in the Placing will be determined through this process. The bookbuilding period for the Placing will commence today with immediate effect and will close at short notice.

In relation to the Placing, the Company has, subject to customary exemptions, agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share issuances. In addition, and also subject to customary exemptions, the two largest shareholders of the Company (funds represented by and/or affiliated with Life Sciences Partners and Draper Esprit, together representing 43.8% of the share capital of the Company) as well as all members of the Company's Management Board and Supervisory Board have agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share disposals.

The Company will announce the number of new shares placed and the subscription price in the Placing in a subsequent press release expected to be published before the beginning of trading on Euronext Amsterdam and Euronext Brussels on Tuesday March 13, 2018.

A registration document, approved by the Netherlands Authority for the Financial Markets (AFM) on March 12, 2018, is available free of charge on the Company's website (www.kiadis.com). A summary and securities note, which together with the registration document will form the listing prospectus on the basis of which the new shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels, will be submitted to the AFM with a view to receiving its approval on or about March 13, 2018, following which it will be made available free of charge on the Company's website (www.kiadis.com).  

Jefferies International Limited is acting as Sole Bookrunner, Canaccord Genuity Limited as Lead Manager, Chardan as Co-Lead Manager and LifeSci Capital LLC as Co-Manager in connection with the Placing. Saola Healthcare Partners is acting as financial advisor to the Company.

*About Kiadis Pharma*
Kiadis Pharma's allodepleted T-cell immunotherapy product, given after a haploidentical hematopoietic stem cell transplantation (HSCT), is designed to reduce Graft versus Host Disease (GVHD). Single dose Phase 2 data with lead product ATIR101(TM) in patients with blood cancer shows a strong and clinically very relevant improvement over literature for the Baltimore protocol, with reduced risk of GVHD. Based on the positive results from the Phase 2 trial, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101(TM) across the EU as an adjunctive treatment in HSCT for malignant disease. Kiadis Pharma received Day 120 questions in September 2017 and is on track for potential (conditional) approval in Q4 2018 and launch in H2 2019. Kiadis Pharma is conducting a Phase 3 trial with ATIR101(TM) across Europe and North America (head to head against the Baltimore protocol). The first patient was enrolled in December 2017.

In September 2017 the US Food and Drug Administration (FDA) granted ATIR101(TM) the Regenerative Medicine Advanced Therapy (RMAT) designation. ATIR101(TM) has been granted Orphan Drug Designations both in the US and Europe.

The Company's shares are listed on Euronext Amsterdam and Brussels under the ticker KDS.

Website: www.kiadis.com

Company presentation: http://www.kiadis.com/company-presentation/

*For more information, please contact:*

*Kiadis Pharma:*
Karl Hård
Head of IR & Communications
Tel. +31 611 096 298
k.hard@kiadis.com  

 

*Important Notices*

This announcement not for distribution, directly or indirectly, in whole or in part, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada, Japan, South Africa or any other jurisdiction where to do so might constitute a violation or breach of any applicable law or regulation. This announcement is not a prospectus for the purposes of the Prospectus Directive (as defined below). This announcement is for information purposes only and is not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy securities of Company in the United States, Australia, Canada, Japan, South Africa or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction, and the distribution of this communication in jurisdictions may be similarly restricted. This announcement should not be regarded as an opinion or recommendation concerning the purchase or sale of securities of the Company. Persons into whose possession this communication comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdictions.

The securities mentioned herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), and may not be offered or sold in the United States absent registration under the US Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the US Securities Act. There will be no public offering of securities in the United States.

In the United Kingdom this announcement is only being distributed to, and is only directed at, and any investment or investment activity to which this announcement relates is available only to, and will be engaged in only with, qualified investors as defined in the Prospectus Directive who are (i) investment professionals falling with Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) other persons to whom it may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). Persons who are not relevant persons should not take any action on the basis of this announcement and should not act or rely on it.

The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area. With respect to any Member State of the European Economic Area and which has implemented the Prospectus Directive (each a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (i) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (ii) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purpose of this paragraph, the expression "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable the investor to decide to exercise, purchase or subscribe for the securities, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State. Notwithstanding the foregoing, in the Netherlands the shares are not and may not be offered other than to persons or entities who or which are qualified investors (gekwalificeerde beleggers) as defined in Section 1:1 of the Dutch Financial Supervision Act (Wet op het financieel toezicht) and in Belgium the shares may not be offered other than to persons or entities who or which are qualified investors as defined in Article 10§1 of the Belgian law dated 16 June 2006 (Wet op de openbare aanbieding van beleggingsinstrumenten en de toelating van beleggingsinstrumenten tot de verhandeling op een gereglementeerde markt).

Any investment decision in connection with the Placing must be made on the basis of all publicly available information relating to the Company and the new shares to be placed. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This announcement does not purport to identify or suggest the risks (direct or indirect) which may be associated with an investment in the Company or the new shares.

The new shares shall be admitted to listing and trading on Euronext Amsterdam on the basis of a listing prospectus, consisting of a registration document (the "Registration Document") and a summary and securities note (the "Summary and Securities Note"). The Registration Document, approved by the AFM on March 12, 2018, is available free of charge on the Company's website (www.kiadis.com). The Summary and Securities Note will contain a description of risks and uncertainties relating to holding shares in the Company. These risks and uncertainties include, among others: (i) the ownership of the Shares is highly concentrated and your interests may conflict with the interests of the Company's significant shareholders; (ii) U.S. and other non-Dutch holders of the Shares may be unable to exercise pre-emptive rights; (iii) the Company does not intend to pay dividends for the foreseeable future; (iv) the Company believes that it was a passive foreign investment company (PFIC) during its 2014, 2015, 2016 and 2017 taxable years and that it may be so as well during its 2018 taxable year, generally resulting in adverse tax consequences to U.S. investors; and (v) any sale, purchase or exchange of Shares may become subject to a common financial transaction tax. The Summary and Securities Note shall be made generally available via the Company's website (www.kiadis.com) if and when approved by the AFM.

In connection with any offering of the new shares, each of Jefferies International Limited ("Jefferies"), Canaccord Genuity Limited ("Canaccord"), Chardan Capital Markets, LLC ("Chardan") and LifeSci Capital LLC ("LifeSci Capital" and, together with Jefferies, Canaccord and Chardan, the "Banks") and any of their respective affiliates acting as an investor for their own account may take up as a proprietary position any new shares and in that capacity may retain, purchase or sell for their own account such new shares. In addition, any of them or their respective affiliates may enter into financing arrangements and swaps with investors in connection with which that any of them (or their affiliates) may from time to time acquire, hold or dispose of new shares. None of the Banks or any of their respective affiliates intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so.

None of the Banks or any of their respective affiliates, directors, officers, employees, advisers and agents accepts any responsibility or liability whatsoever for/or makes any representation or warranty, express or implied, as to the truth, fullness, accuracy or completeness of the information in this document (or whether any information has been omitted from the document) or any other information relating to the Company or its associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

None of the Company, the Banks or any of their respective affiliates directors, officers, employees, agents, affiliates or advisers is under any obligation to update, complete, revise or keep current the information contained in this document to which it relates or to provide the recipient of with access to any additional information that may arise in connection with it.

Jefferies and Canaccord are each authorised and regulated in the United Kingdom by the Financial Conduct Authority. Each of the Banks is acting exclusively for the Company and no one else in connection with this announcement or any future transaction in connection with it.

None of the Banks or any of their respective affiliates will regard any other person (whether or not a recipient of this document) as a client or will be responsible to anyone other than the Company for providing the protections afforded to its clients or for the giving of advice in relation to the contents of this announcement or any transaction, matter or arrangement referred to in this announcement.

The Company's managing director and CEO Arthur Lahr is responsible for arranging for the release of this announcement on behalf of Kiadis Pharma N.V.

This announcement contains statements about the Company that are or may be forward-looking statements. All statements other than statements of historical facts included in this announcement may be forward-looking statements. Without limitation, any statements preceded or followed by or that include the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or words or terms of similar substance or the negative thereof are forward-looking statements. These forward-looking statements are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of any such person to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions. No undue reliance should be placed on any forward-looking statement, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to the Company or any persons acting on their behalf are expressly qualified in their entirety by this statement. Reported by GlobeNewswire 55 minutes ago.

Indian batting comes a cropper in Mithali's absence

0
0
India's ploy with the ball also didn't go as per plan as Australia hammered the hosts in the first ODI Reported by CricBuzz 35 minutes ago.

Sport24.co.za | 12 years ago! The greatest ODI ever played - '438'

0
0
Twelve years ago today, Herschelle Gibbs and the Proteas did the unthinkable - they chased down a mammoth ODI total to beat Australia at the Wanderers. Reported by News24 43 minutes ago.

Olympus Stem Cells Pty Ltd: Olympus Stem Cells Achieving 100% Stem Cell Viability Confirmed with Muse Analyzer Testing

0
0
SYDNEY, AUSTRALIA / ACCESSWIRE / March 12, 2018 / Medical clinic and research facility Olympus Stem Cells Pty Ltd, based in Sydney Olympic Park, NSW, Australia, are pleased to announce the validati... Reported by FinanzNachrichten.de 35 minutes ago.

How an Australian bank laundered money for Hong Kong drug gangs

0
0
The Commonwealth Bank of Australia allowed cash deposits without legal safeguards Reported by FT.com 10 minutes ago.

Stratfor Forecasts Global Trade Offensive and Retaliation to Shape Key Geopolitical Trends in Second Quarter of 2018

0
0
AUSTIN, Texas, March 12, 2018 (GLOBE NEWSWIRE) -- Stratfor, the world’s leading geopolitical intelligence platform, forecasts a U.S.-led global trade offensive, retaliation and associated repercussions to primarily shape international affairs in the second quarter of 2018. Stratfor’s 2018 Second-Quarter Forecast, designed to help companies, governments and globally engaged individuals stay focused on strategic plans while identifying key geopolitical risks and opportunities, builds upon Stratfor’s 2018 Annual Forecast released at the beginning of the year.“The White House is ready to take aim at the global economy this quarter and the bull’s-eye is sitting squarely on Beijing,” said Stratfor Vice President of Global Analysis Reva Goujon, noting that many nations, to include some U.S. allies, will retaliate by targeting politically sensitive sectors. “In addition to imposing its own restrictions on some U.S. agricultural goods, Beijing is likely to selectively apply regulatory pressure on American companies with stakes in China.”

Stratfor’s forecast for the second quarter identifies the key geopolitical trends that will fundamentally shape and constrain the actions of both nations and industries in the months ahead. Updated with strategic analysis and other guidance throughout the year on Stratfor Worldview, the forecasts helps individual, team and enterprise members cut through daily information noise and focus on what’s truly significant versus merely important.

Additional developments Stratfor forecasts for the second quarter include:

· Tension between the United States and China will spike, putting businesses caught in the fray at risk.
· The development of disruptive weapons technology among the United States, China and Russia will further degrade the world’s arms control treaties.
· Building upon a brief détente, South Korea will try to persuade the United States and North Korea to reconcile their positions on denuclearization.
· Debate over eurozone reforms will expose the deeper divides threatening European unity.
· Trade tensions will mar Washington’s rocky relationship with Brazil over how to manage Venezuela’s economic crisis.
· China’s wide maritime reach will draw India into closer defense cooperation with the United States, Japan and Australia.
· Turkey will push its troops deeper into northern Syria and Iraq while laying claim to the eastern Mediterranean Sea.

The complete 2018 Second-Quarter Forecast is now available on Stratfor Worldview. Accurate calls from the 2018 Annual Forecast thus far include: the Trump administration launching its protectionist trade agenda, Chinese President Xi Jinping moving to maintain his unrivaled authority, India teaming up with China’s regional rivals, Saudi Crown Prince Mohammed bin Salman making good on his promise of aggressive economic reform, and South African President Jacob Zuma’s resignation.

*About Stratfor*
As the world's leading geopolitical intelligence platform, Stratfor brings valuable context to global events, empowering businesses, governments and individuals to more confidently navigate their way through an increasingly complex international environment. By leveraging a deep understanding of history, politics and geography in conjunction with our unique methodology, Stratfor delivers informed perspectives on today's events and develops a more accurate view of the future. Information about individual, team and enterprise membership is available at Stratfor.com.

*For more information, contact*:
Joshua Cook
Stratfor Director of Public Relations
pr@stratfor.com
512.744.4309 Reported by GlobeNewswire 5 hours ago.

Golf-Els to captain Internationals at 2019 Presidents Cup

0
0
March 12 (Reuters) - South African Ernie Els will be captain of the International team for next year's Presidents Cup at Royal Melbourne Golf Club in Australia, a source told Reuters on Monday. Reported by Reuters India 4 hours ago.
Viewing all 53225 articles
Browse latest View live




Latest Images